CD32-chimeric receptor T cell identifies CD32 cell surface ligand(s), on breast cancer (BC) cells, leading to BC cell elimination in vitro and in vivo and allowing detection of genes prognostically relevant. This evidence concerns the gene FCGR2A and breast cancer.